Long term inhibition of hip joint damage under tumor necrosis factor-alpha inhibitors in spondyloarthritis-Reference-Cited by-同舟云学术

Long term inhibition of hip joint damage under tumor necrosis factor-alpha inhibitors in spondyloarthritis

Published:2020-11 Issue: Volume:88 Page:106927
ISSN:1567-5769
Container-title:International Immunopharmacology
language:en
Short-container-title:International Immunopharmacology

Author:

Mahmoud Ines,Maatallah Kaouther,Ben Nessib Dorra,Belghali Safa,Ben Abdelghani Kawther,Metoui Leila,Saidane Olfa,Hamdi Wafa,Zouari Bechir,Ben Salem Kamel,Tekaya Rawdha,Abdelmoula Leila

Publisher

Elsevier BV

Subject

Pharmacology,Immunology,Immunology and Allergy

Reference24 articles.

1. Prevalence and characteristics of hip involvement in spondyloarthritis: a single-centre observational study of 275 patients;Burki;Clin. Exp. Rheumatol.-Incl Suppl.,2012

2. Hip disease in ankylosing spondylitis;Vander Cruyssen;Curr. Opin. Rheumatol.,2013

3. Management of hip involvement in ankylosing spondylitis;Guan;Clin. Rheumatol.,2013

4. Revision total hip arthroplasty: the patient’s perspective;Barrack;Clin. Orthop.,2006

5. Treatment efficacy of etanercept and MTX combination therapy for ankylosing spondylitis hip joint lesion in Chinese population;Lian;Rheumatol. Int.,2012

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Factors associated with poor prognosis of hip arthritis in juvenile idiopathic arthritis: Data from the JIR cohort;Musculoskeletal Care;2023-03-10

2. Comment on “Hip involvement in children with enthesitis-related arthritis (ERA) is associated with poor outcomes in adulthood”;Clinical Rheumatology;2022-01-21

3. The Clinical and MRI Effect of TNF-α Inhibitors in Spondyloarthritis Patients With Hip Involvement: A Real-World Observational Clinical Study;Frontiers in Immunology;2021-09-29

4. Correction to: Rebuttal letter on “Comment on tumor necrosis factor inhibitors prevent structural damage in hips in ankylosing spondylitis—time to reconsider treatment guidelines? A case series and review of literature”;Clinical Rheumatology;2021-05-04

5. Comment on “Tumor necrosis factor inhibitors prevent structural damage in hips in ankylosing spondylitis—time to reconsider treatment guidelines? A case series and review of literature”;Clinical Rheumatology;2021-03-22